Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.201
-0.009 (-4.29%)
At close: Apr 28, 2026, 4:00 PM EDT
0.200
-0.001 (-0.50%)
After-hours: Apr 28, 2026, 7:31 PM EDT
Sangamo Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 39.55 | 57.8 | 176.23 | 111.3 | 110.7 | Upgrade
|
| Revenue Growth (YoY) | -31.57% | -67.20% | 58.34% | 0.54% | -6.34% | Upgrade
|
| Cost of Revenue | 112.67 | 111.32 | 230.46 | 249.9 | 230.82 | Upgrade
|
| Gross Profit | -73.12 | -53.52 | -54.23 | -138.6 | -120.12 | Upgrade
|
| Selling, General & Admin | 34.89 | 44.73 | 60.07 | 62.68 | 63.22 | Upgrade
|
| Operating Expenses | 34.89 | 44.73 | 60.07 | 62.68 | 63.22 | Upgrade
|
| Operating Income | -108 | -98.25 | -114.29 | -201.28 | -183.34 | Upgrade
|
| Interest & Investment Income | 1.3 | 1.51 | 8.25 | 6.43 | 5.35 | Upgrade
|
| Currency Exchange Gain (Loss) | -3.7 | 1.6 | 2.85 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.14 | 2.75 | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -110.27 | -92.39 | -103.19 | -194.85 | -177.99 | Upgrade
|
| Merger & Restructuring Charges | - | -0.2 | -4.7 | - | - | Upgrade
|
| Impairment of Goodwill | - | - | -38.14 | - | - | Upgrade
|
| Asset Writedown | -13.24 | -5.52 | -116.88 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | 3 | - | Upgrade
|
| Pretax Income | -123.5 | -98.11 | -262.9 | -191.85 | -177.99 | Upgrade
|
| Income Tax Expense | -0.57 | -0.17 | -5.07 | 0.43 | 0.31 | Upgrade
|
| Earnings From Continuing Operations | -122.93 | -97.94 | -257.83 | -192.28 | -178.3 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | 0.01 | Upgrade
|
| Net Income | -122.93 | -97.94 | -257.83 | -192.28 | -178.29 | Upgrade
|
| Net Income to Common | -122.93 | -97.94 | -257.83 | -192.28 | -178.29 | Upgrade
|
| Shares Outstanding (Basic) | 280 | 202 | 174 | 154 | 145 | Upgrade
|
| Shares Outstanding (Diluted) | 280 | 202 | 174 | 154 | 145 | Upgrade
|
| Shares Change (YoY) | 38.92% | 15.62% | 13.02% | 6.76% | 7.53% | Upgrade
|
| EPS (Basic) | -0.44 | -0.49 | -1.48 | -1.25 | -1.23 | Upgrade
|
| EPS (Diluted) | -0.44 | -0.49 | -1.48 | -1.25 | -1.23 | Upgrade
|
| Free Cash Flow | -97.31 | -67.41 | -246 | -243.8 | -256.53 | Upgrade
|
| Free Cash Flow Per Share | -0.35 | -0.33 | -1.41 | -1.58 | -1.77 | Upgrade
|
| Gross Margin | -184.86% | -92.60% | -30.77% | -124.53% | -108.51% | Upgrade
|
| Operating Margin | -273.07% | -169.98% | -64.85% | -180.85% | -165.62% | Upgrade
|
| Profit Margin | -310.81% | -169.45% | -146.30% | -172.76% | -161.05% | Upgrade
|
| Free Cash Flow Margin | -246.03% | -116.62% | -139.59% | -219.05% | -231.73% | Upgrade
|
| EBITDA | -104.04 | -93.14 | -99.23 | -189.17 | -173.9 | Upgrade
|
| EBITDA Margin | -263.05% | -161.14% | -56.31% | -169.97% | -157.09% | Upgrade
|
| D&A For EBITDA | 3.96 | 5.11 | 15.07 | 12.11 | 9.44 | Upgrade
|
| EBIT | -108 | -98.25 | -114.29 | -201.28 | -183.34 | Upgrade
|
| EBIT Margin | -273.07% | -169.98% | -64.85% | -180.85% | -165.61% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.